-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Protagonist's ICOTYDE Demonstrates Increasing PASI 100 Rates Through Week 52 And Nearly 60% Complete Skin Clearance In Adolescents In Phase 3 ICONIC Program

Benzinga·03/30/2026 07:35:17
Listen to the news
  • One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once-daily pill for moderate-to-severe plaque psoriasis
  • Results further support the differentiated profile of ICOTYDE, the first and only IL-23 receptor-targeted oral peptide